Subscribe Login
A-Brands

Nestlé Ireland To Raise Funds For Cancer Trials Ireland

By Donna Ahern
Nestlé Ireland To Raise Funds For Cancer Trials Ireland

Nestlé Ireland has announced Cancer Trials Ireland as its new 'Staff Charity of the Year'.

The confectionary giant noted that its aim is to raise over €100,000 to assist Cancer Trials Ireland in their work to provide every patient diagnosed with cancer access to high-quality and potentially life-altering cancer trials.

The announcement is part of Nestlé’s community partnership programme which involves Nestlé Ireland supporting worthy causes that make a real difference in communities nationwide.

Staff Vote 

Staff at Nestlé Ireland’s Citywest HQ selected Cancer Trials Ireland following an internal vote with staff committing to a range of awareness and fundraising initiatives over the duration of the partnership.

ADVERTISEMENT

To date, almost 31,000 (30,770) people have taken part in nearly 800 (786) cancer clinical trials, the company explained.

Nestlé Ireland is committed to being a force for good and our staff charity programme is a demonstration of this commitment in action," Kieran Conroy, country manager, Nestlé Ireland, said. 

"Since we launched the Charity of the Year Programme a number of years ago, our staff have raised over €750,000 for a range of important causes which are making a valuable impact on the lives of people in communities across Ireland." 

Additional Funding 

Cancer Trials Ireland is partly funded by the Health Research Board and the Irish Cancer Society.

ADVERTISEMENT

It also receives income from pharmaceutical companies and international research groups, as well through philanthropic giving and donations from members of the public.

© 2022 Checkout – your source for the latest Irish retail news. Article by Donna Ahern. For more A-brand news, click here. Click subscribe to sign up for the Checkout print edition.

Stay Connected With Our Weekly Newsletter

Processing your request...

Thanks! please check your email to confirm your subscription.